Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 3

Active, not recruiting

Conditions: Ulcerative Colitis
Ulcerative Colitis Chronic

Interventions: Drug: Mirikizumab

First Posted Date: 2023-03-14

Last Posted Date: 2024-08-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 160

Registration Number: NCT05767021

Locations: 🇺🇸
Advanced Research Associates, LLC, Miami, Florida, United States
🇺🇸
Gastroenterology Research of San Antonio, San Antonio, Texas, United States
🇺🇸
Southern Star Research Institute, LLC, San Antonio, Texas, United States

and more 117 locations

A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [¹⁴C]-LY3437943

First Posted Date: 2023-03-07

Last Posted Date: 2023-07-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 7

Registration Number: NCT05757531

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [¹⁴C]-LY3372689

First Posted Date: 2023-03-01

Last Posted Date: 2023-04-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 8

Registration Number: NCT05749848

Locations: 🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Phase 3

Active, not recruiting

Conditions: Alzheimer's Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

Interventions: Drug: Donanemab
Drug: Placebo

First Posted Date: 2023-02-22

Last Posted Date: 2024-07-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 800

Registration Number: NCT05738486

Locations: 🇺🇸
Irvine Clinical Research, Irvine, California, United States
🇺🇸
Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States
🇺🇸
Palm Beach Neurology, West Palm Beach, Florida, United States

and more 43 locations

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Phase 3

Conditions: Atopic Dermatitis
Eczema

Interventions: Drug: Lebrikizumab
Drug: Placebo

First Posted Date: 2023-02-21

Last Posted Date: 2024-08-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 250

Registration Number: NCT05735483

Locations: 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇨🇦
DermEdge Research, Mississauga, Ontario, Canada

and more 91 locations

A Study of LY3848575 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3848575

First Posted Date: 2023-02-14

Last Posted Date: 2024-04-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT05727072

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Phase 3

Recruiting

Conditions: Areata Alopecia
Skin Diseases
Hypotrichosis
Alopecia
Hair Diseases
Pathological Conditions, Anatomical

Interventions: Drug: Placebo
Drug: Baricitinib

First Posted Date: 2023-02-10

Last Posted Date: 2024-08-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 595

Registration Number: NCT05723198

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States

and more 146 locations

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Type 2 Diabetes

Interventions: Drug: Tirzepatide

First Posted Date: 2023-01-31

Last Posted Date: 2024-12-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 152

Registration Number: NCT05706506

Locations: 🇺🇸
Velocity Clinical Research, Huntington Park, Los Angeles, California, United States
🇺🇸
Versailles Family Medicine, Versailles, Kentucky, United States
🇺🇸
Texas Diabetes & Endocrinology, P.A., Austin, Texas, United States

and more 28 locations

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2023-01-25

Last Posted Date: 2024-10-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT05696847

Locations: 🇺🇸
Atlanta Center of Medical Research, Atlanta, Georgia, United States
🇺🇸
Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

A Study of Continuous Blood Pressure Monitoring in Healthy Participants

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Propranolol
Drug: Pseudoephedrine
Device: ABPM and Wearable Novel Devices
Other: No Intervention

First Posted Date: 2023-01-20

Last Posted Date: 2023-04-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT05692869

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy